Jennifer

Interview Transcript "I began coaching little league girl's softball about five years ago.

I was diagnosed with non-Hodgkin's lymphoma in December of 2005. I was Stage IV, the diffuse large B-cell type of non-Hodgkin's lymphoma.

I have a daughter who was three years old when I was diagnosed, and I was scared to death that I would not be there to see her grow up.

I went to the Mayo Clinic and had a consultation with one of their oncologists.

Just prior to the first treatment, I remember walking into the doctor's office thinking, 'Is this the last time I'm going to feel good?' It means so much every day that I wake up and I think, 'Gosh, I feel great.'"

Product Indication: Rituxan® (Rituximab) is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) as a single agent; for previously untreated diffuse large B-cell, CD20-positive, NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens; for previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy; and for the treatment of non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent, after first-line CVP chemotherapy.

Important Safety Information: Rituxan can result in fatal infusion reactions, tumor lysis syndrome, severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation with related fulminant hepatitis and other serious viral infections, cardiac arrhythmias, renal toxicity and bowel obstruction and perforation.

The most common adverse events (incidence ≥ 25%) were infusion reactions, fever, chills, infection, asthenia, and lymphopenia. The incidence of infusion reactions was highest during the first infusion and decreased with each subsequent infusion. These reactions generally have resolved with slowing or interruption of the infusion and with supportive care.

Please see the full Product Information, including Boxed WARNINGS, for additional safety information.

Individual results may vary.